About Naurex
Naurex is a company based in Evanston (United States) founded in 2008 by Joseph Moskal was acquired by Allergan in July 2015. Naurex has raised $162.11 million across 5 funding rounds from investors including Takeda Pharmaceuticals, Baxter and TD Securities. Naurex operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Evanston, United States
- Founders Joseph Moskal
- SectorsHealthcare
- Website naurex.com
- Social LinkedIn
- Acquired by Allergan (Jul 2015)
- Legal Name Naurex Inc.
- Total Equity Funding$162.11M (USD)
in 5 rounds
- Latest Funding Round$80M (USD), Series C
Dec 2015
- InvestorsTakeda Pharmaceuticals
& 14 more
- Acquired byAllergan
(Jul 2015)
Funding Insights of Naurex
Naurex has successfully raised a total of $162.11M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $162.11M
- Total Rounds 5
- Last Round Series C — $80M
- First Round $1.11M
(Feb 2011)
- Investors Count 14
All 5 funding rounds of Naurex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $80M | Series C | – | EcoR1, Cowen | |
| May 2014 | $25M | Series B | – | Takeda Ventures, Lundbeck | |
| Dec 2012 | $38M | Series B | – | Baxter Ventures | |
| May 2011 | $18M | Series A | – | Adams Street Partners, LVP | |
| Feb 2011 | $1.11M | Seed | – | – | – |
15 investors in total: 15 institutional.
Investors in Naurex
Naurex has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, Baxter and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private markets investment management with strategies in equity, credit, and secondary investments. | – | adamsstreetpartners.com | - | |
- | – | druidbio.com | - | |
Early-stage life sciences companies are supported through venture capital investments. | – | genesyscapital.com | Toronto, Canada | |
Savitr Capital is focused on direct capital investments. | – | savitrcapital.com | San Francisco, United States | |
- | – | takedaventures.com | - | |
Early-stage healthcare startups are supported with venture capital. | – | lvpcapital.com | San Ramon, United States | |
- | – | baxter.com/inside-baxter/science/programs/baxter-ventures.page | - | |
- | – | ecor1cap.com | - | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
- | – | portolapartners.com | - |
Investor details for Naurex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Naurex
3 people are tracked at Naurex (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Joseph Moskal | Founder | Leadership |
Lee Bastin | Director, Clinical Research | Leadership |
Susan Riley Leppard | Lead CRA / CRA Manager | Team |
Complete people profiles for Naurex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Naurex
4 dated milestones of Naurex across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Naurex is founded.
- Funding First funding round of $1.1M.
- Exit Acquired by Allergan.
- Funding Latest funding round, Series C, of $80.0M.
Competitors of Naurex
Naurex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. | |
| cerecor.com | 2011 | Baltimore, United States | $45.2M | 20 | Therapeutics for immunological and neurological disorders are developed. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| vandapharma.com | 2003 | – | $33.5M | 203 | Pharmaceutical products for CNS disorders are developed and commercialized. | |
| hmnc-brainhealth.com | 2010 | Munich, Germany | $24.64M | – | Targeted therapies and personalized tests for neuropsychiatric disorders are developed. | |
| evecxia.com | 2013 | Durham, United States | $14.85M | – | Therapies for CNS disorders are developed by Evecxia Therapeutics. |
Detailed competitors of Naurex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Naurex
Complete news archive for Naurex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Naurex
10 companies that operate in the same segment as Naurex (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Naurex
Naurex was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Naurex is headquartered in Evanston, United States. It is registered at Evanston, Illinois, United States.
Naurex is a funded company, having raised a total of $162.11M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.11M, raised on Feb 2011.
Naurex was founded in 2008 in Evanston, United States, as a clinical-stage biopharmaceutical entity. Focus is placed on developing treatments for depression and other central nervous system disorders. The lead candidate, Rapastinel, is advanced through late-stage trials for use as an adjunctive therapy in major depressive disorder. An oral second-generation compound, NRX-1074, is evaluated in Phase 2 trials as a monotherapy for major depressive disorder.
Naurex's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Naurex has 15 investors. Key investors include Takeda Pharmaceuticals, Baxter, TD Securities, Lundbeck, and Northwestern University.
Naurex operates through Naurex Inc..
Yes. Naurex was acquired by Allergan in July 2015.